HDAC9 and cancer: These compounds, including vorinostat (suberoylanilide hydroxamic acid, SAHA) and Romidepsin (cyclic tetrapeptide) which revealed a promising HDAC inhibition against different type of cancers were approved for the treatment of cutaneous T-cell lymphoma [102,103,104,105].